Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M97,636Revenue $M16,385Net Margin (%)16.9Z-Score5.6
Enterprise Value $M98,141EPS $1.5Operating Margin %17.1F-Score5
P/E(ttm))36.2Cash Flow Per Share $2.8Pre-tax Margin (%)20.6Higher ROA y-yN
Price/Book6.510-y EBITDA Growth Rate %0.7Quick Ratio1.6Cash flow > EarningsY
Price/Sales6.15-y EBITDA Growth Rate %-13.3Current Ratio1.8Lower Leverage y-yN
Price/Cash Flow11.7y-y EBITDA Growth Rate %14.6ROA % (ttm)7.7Higher Current Ratio y-yY
Dividend Yield %2.5Insider Buy (3m)0ROE % (ttm)17.9Less Shares Outstanding y-yN
Payout Ratio %88.0Shares Outstanding M1,659ROI % (ttm)5.7Gross Margin Increase y-yY

Gurus Latest Trades with BMY

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMYVanguard Health Care Fund 2014-09-30 Add0.3%$47.86 - $51.96
($49.97)
$ 58.8618%Add 6.31%38,480,761
BMYRay Dalio 2014-09-30 Buy $47.86 - $51.96
($49.97)
$ 58.8618%New holding, 10228 sh.10,228
BMYJoel Greenblatt 2014-09-30 Sold Out -0.05%$47.86 - $51.96
($49.97)
$ 58.8618%Sold Out0
BMYVanguard Health Care Fund 2014-06-30 Add0.86%$46.59 - $52.19
($49.29)
$ 58.8619%Add 22.96%36,197,961
BMYJoel Greenblatt 2014-06-30 Buy 0.05%$46.59 - $52.19
($49.29)
$ 58.8619%New holding, 89363 sh.89,363
BMYRay Dalio 2014-06-30 Sold Out $46.59 - $52.19
($49.29)
$ 58.8619%Sold Out0
BMYKen Fisher 2014-06-30 Add$46.59 - $52.19
($49.29)
$ 58.8619%Add 216.1%49,732
BMYRonald Muhlenkamp 2014-03-31 Buy 1.9%$48.54 - $56.61
($53.23)
$ 58.8611%New holding, 212015 sh.212,015
BMYVanguard Health Care Fund 2014-03-31 Add0.73%$48.54 - $56.61
($53.21)
$ 58.8611%Add 20.35%29,437,761
BMYRay Dalio 2014-03-31 Buy $48.54 - $56.61
($53.23)
$ 58.8611%New holding, 4428 sh.4,428
BMYGeorge Soros 2014-03-31 Sold Out -0.05%$48.54 - $56.61
($53.23)
$ 58.8611%Sold Out0
BMYJoel Greenblatt 2014-03-31 Sold Out -0.02%$48.54 - $56.61
($53.23)
$ 58.8611%Sold Out0
BMYJoel Greenblatt 2013-12-31 Buy 0.02%$46.41 - $53.84
($50.96)
$ 58.8616%New holding, 11679 sh.11,679
BMYVanguard Health Care Fund 2013-09-30 Add0.64%$41.32 - $47.53
($43.84)
$ 58.8634%Add 20.26%24,459,861
BMYIrving Kahn 2013-09-30 Reduce-0.19%$41.32 - $47.53
($43.84)
$ 58.8634%Reduce -48.95%28,300
BMYJean-Marie Eveillard 2013-09-30 Reduce-0.01%$41.32 - $47.53
($43.84)
$ 58.8634%Reduce -75.17%16,520
BMYVanguard Health Care Fund 2013-06-30 Add0.39%$39.68 - $47.68
($43.41)
$ 58.8636%Add 13.32%20,338,461
BMYGeorge Soros 2013-06-30 Buy 0.05%$39.68 - $47.68
($43.41)
$ 58.8636%New holding, 100000 sh.100,000
BMYJean-Marie Eveillard 2013-06-30 Add0.01%$39.68 - $47.68
($43.41)
$ 58.8636%Add 302.66%66,520
BMYIrving Kahn 2013-06-30 Reduce-2.17%$39.68 - $47.68
($43.41)
$ 58.8636%Reduce -86.62%55,433
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BMY Ray Dalio 2014-09-3010,22800New Buy
BMY Dodge & Cox 2014-09-3090,4280.010+14.58%
BMY Vanguard Health Care Fund 2014-09-3038,480,7612.325+6.31%
BMY Mario Gabelli 2014-09-30700,2550.040.19+3.79%
BMY Brian Rogers 2014-09-306,264,8000.381.2+3.3%
BMY Ken Fisher 2014-09-3051,20100.01+2.95%
BMY Irving Kahn 2014-09-3027,65000.23
BMY Jean-Marie Eveillard 2014-09-3014,49200
BMY Ronald Muhlenkamp 2014-09-30212,4850.012-0.13%
BMY Joel Greenblatt 2014-09-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


BMY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ANDREOTTI LAMBERTOCEO 2014-11-05Sell75,000$57.791.85view
ANDREOTTI LAMBERTOCEO 2014-10-24Sell50,000$5311.06view
CORNELIUS JAMES MDirector 2014-10-15Sell100,000$48.9220.32view
ANDREOTTI LAMBERTOCEO 2014-10-06Sell50,000$50.9915.43view
Cuss Francis MEVP & CSO 2014-09-16Sell63,667$50.7715.93view
Caforio GiovanniCOO 2014-09-15Sell26,691$49.8718.03view
Caldarella Joseph CSVP & Controller 2014-09-10Sell7,415$51.0315.34view
ANDREOTTI LAMBERTOCEO 2014-09-08Sell50,000$51.0515.3view
von Autenried PaulSVP, Enterp. Services & CIO 2014-08-19Sell20,000$49.8917.98view
Bancroft Charles AEVP & CFO 2014-07-29Sell67,621$51.0615.28view

Press Releases about BMY :

    Quarterly/Annual Reports about BMY:

    News about BMY:

    Articles On GuruFocus.com
    A Buy Recommendation From Absolute Valuation Model to Bristol-Myers Squibb Nov 24 2014 
    Blackhill Bets Almost Half of Portfolio on Williams-Sonoma Nov 10 2014 
    A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio Nov 09 2014 
    Weekly CFO Sells Highlight: Williams Companies Inc, Google Inc, Bristol-Myers Squibb Company Oct 19 2014 
    The Six Types of Winning Stocks Oct 17 2014 
    Bristol-Myers: Absolute Valuation Model versus Relative Valuation Model Aug 29 2014 
    Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
    UnitedHealth Group Up on Weak Day for the Dow Jul 17 2014 
    Pharma Sector Stocks To Consider For Sustained Returns Jun 25 2014 
    Johnson & Johnson (JNJ) Dividend Stock Analysis May 29 2014 


    More From Other Websites
    Five Prime Therapeutics Up on Deal with Bristol-Myers Nov 26 2014
    Bristol-Myers: FDA blocks hepatitis C drug for now Nov 26 2014
    Bristol-Myers: FDA blocks hepatitis C drug for now Nov 26 2014
    Bristol-Myers Hepatitis C Drug Needs More Data on Combinations Nov 26 2014
    FDA Seeks More Data on Bristol-Myers Hepatitis C Therapy Nov 26 2014
    FDA declines to approve Bristol-Myers hepatitis drug Nov 26 2014
    11:34 am Bristol-Myers announced that the FDA has issued a Complete Response Letter regarding the... Nov 26 2014
    Bristol-Myers Squibb Receives Complete Response Letter from U.S. Food and Drug Administration for... Nov 26 2014
    Five Prime in cancer drug deal with Bristol-Myers Nov 24 2014
    Five Prime in cancer drug deal with Bristol-Myers Nov 24 2014
    A Buy Recommendation From Absolute Valuation Model to Bristol-Myers Squibb Nov 24 2014
    Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to... Nov 24 2014
    Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to... Nov 24 2014
    Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to... Nov 24 2014
    Thursday’s Notable Options Activity Nov 21 2014
    Screening Pharma Stocks Amid Turnaround Nov 19 2014
    Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naive Advanced Melanoma Patients... Nov 18 2014
    [$$] India Divided on Whether to Break Bristol-Myers Drug Patent Nov 18 2014
    Allied-Bristol Life Sciences Forms Strategic Partnership with Synergy Partners R&D Solutions to... Nov 18 2014
    Bristol-Myers Squibb Reports Positive Opdivo Phase III Data Nov 17 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK